<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6683">
  <stage>Registered</stage>
  <submitdate>14/08/2017</submitdate>
  <approvaldate>14/08/2017</approvaldate>
  <nctid>NCT03264651</nctid>
  <trial_identification>
    <studytitle>Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density</studytitle>
    <scientifictitle>A Single-Centre Pilot Trial Investigating the Efficacy and Safety of Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CH02ST1</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Mammographic Density</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - enobosarm

Experimental: oral enobosarm and anastrozole - 9 mg of oral enbosarm and 1 mg of anastrozole daily


Treatment: drugs: enobosarm
Oral combination therapy of enobosarm and anastrozole

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Mammographic breast density - Volumetric analysis of fibroglandular density change on mammography utilizing Volpara software</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Breast tissue elasticity - Evaluation of breast elasticity change by direct shear wave ultrasonic measurement</outcome>
      <timepoint>1 month</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Breast tissue elasticity - Evaluation of breast elasticity change by direct shear wave ultrasonic measurement</outcome>
      <timepoint>3 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Breast tissue elasticity - Evaluation of breast elasticity change by direct shear wave ultrasonic measurement</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Breast pain scale - Breast pain measured on a 100 mm visual analog scale</outcome>
      <timepoint>1 month, 3 months, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum gonadotropin levels - serum follicular stimulating hormone and luteinizing hormone levels</outcome>
      <timepoint>1 month, 3 months, 12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Menopausal symptoms - Menopause symptoms as recorded on a menopause symptoms scale</outcome>
      <timepoint>3 months, 12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Provision of written informed consent

          -  Pre-menopausal levels of FSH/LH/E2 (follicle stimulating hormone, luteinizing hormone,
             oestrogen) according to the definition of "pre-menopausal range" for the laboratory
             involved

          -  Have a Volpara Density volumetric breast density of &gt;15.5% (combined average both
             breasts)

          -  Breast pain in the previous month of equal to or greater than 40mm on a 100mm visual
             analogue pain scale

          -  WBC = 3.0 x 109/L, granulocytes = 1.5 X 109/L and platelets = 100 x 109/L.

          -  AST/SGOT or ALT/SGPT = 3 times ULN

          -  eGFR&gt; 60 ml/min/1.73m2

          -  Negative pregnancy test in women of childbearing potential (premenopausal or less than
             12 months of amenorrhea post-menopause, and who have not undergone surgical
             sterilization), no more than 7 days before the first dose of study treatment;

          -  For women of childbearing potential who are sexually active, agreement to use a highly
             effective, non-hormonal form of contraception during and for at least 6 months after
             completion of study treatment; OR, a fertile male partner willing and able to use
             effective non-hormonal means of contraception (barrier method of contraception in
             conjunction with spermicidal jelly, or surgical sterilization) during and for at least
             6 months after completion of study treatment;</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Presence of breast cancer

          -  Diabetes mellitus or glucose intolerance defined as a fasting glucose &gt;6mmol/l

          -  Previous or concomitant other (non-breast cancer) malignancy within the previous 5
             years (other than skin cancer)

          -  History of coronary artery disease

          -  Systemic hormonal contraception

          -  Risk of transmitting Human Immunodeficiency Virus or viral hepatitis via infected
             blood

          -  Known hypersensitivity to any component of testosterone

          -  Unable to comply with study requirements

          -  Prolonged systemic corticosteroid treatment

          -  Any investigational drugs

          -  Systemic hormone replacement therapy

          -  Pregnant or lactating women

          -  Known liver disease

          -  Current warfarin usage</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/03/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Wellend Health - Toorak Gardens</hospital>
    <postcode>5065 - Toorak Gardens</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Havah Therapeutics Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>GTx</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate the impact of a selective androgen receptor modulator combined with an aromatase
      inhibitor in reducing high mammographic breast density.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03264651</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Stephen N Birrell, MD PhD</name>
      <address>Havah Therapeutics Pty Ltd</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Stephen n Birrell, MD PhD</name>
      <address />
      <phone>+61419804741</phone>
      <fax />
      <email>sb@havahtx.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>